TY - JOUR T1 - Image-based & machine learning-guided multiplexed serology test for SARS-CoV-2 JF - medRxiv DO - 10.1101/2022.09.08.22279729 SP - 2022.09.08.22279729 AU - Vilja PietiƤinen AU - Minttu Polso AU - Ede Migh AU - Christian Guckelsberger AU - Maria Harmati AU - Akos Diosdi AU - Laura Turunen AU - Antti Hassinen AU - Swapnil Potdar AU - Annika Koponen AU - Edina Gyukity Sebestyen AU - Ferenc Kovacs AU - Andras Kriston AU - Reka Hollandi AU - Katalin Burian AU - Gabriella Terhes AU - Adam Visnyovszki AU - Eszter Fodor AU - Zsombor Lacza AU - Anu Kantele AU - Pekka Kolehmainen AU - Laura Kakkola AU - Tomas Strandin AU - Lev Levanov AU - Olli Kallioniemi AU - Lajos Kemeny AU - Ilkka Julkunen AU - Olli Vapalahti AU - Krisztina Buzas AU - Lassi Paavolainen AU - Peter Horvath AU - Jussi Hepojoki Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/09/09/2022.09.08.22279729.abstract N2 - Here, we describe a scalable and automated, high-content microscopy -based mini-immunofluorescence assay (mini-IFA) for serological testing i.e., detection of antibodies. Unlike conventional IFA, which often relies on the use of cells infected with the target pathogen, our assay employs transfected cells expressing individual viral antigens. The assay builds on a custom neural network-based image analysis pipeline for the automated and multiplexed detection of immunoglobulins (IgG, IgA, and IgM) in patient samples. As a proof-of-concept, we employed high-throughput equipment to set up the assay for measuring antibody response against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with spike (S), membrane (M), and nucleo (N) proteins, and the receptor-binding domain (R) as the antigens. We compared the automated mini-IFA results from hundreds of patient samples to the visual observations of human experts and to the results obtained with conventional ELISA. The comparisons demonstrated a high correlation to both, suggesting high sensitivity and specificity of the mini-IFA. By testing pre-pandemic samples and those collected from patients with RT-PCR confirmed SARS-CoV-2 infection, we found mini-IFA to be most suitable for IgG and IgA detection. The results demonstrated N and S proteins as the ideal antigens, and the use of these antigens can serve to distinguish between vaccinated and infected individuals. The assay principle described enables detection of antibodies against practically any pathogen, and none of the assay steps require high biosafety level environment. The simultaneous detection of multiple Ig classes allows for distinguishing between recent and past infection.Public abstract The manuscript describes a miniaturized immunofluorescence assay (mini-IFA) for measuring antibody response in patient blood samples. The automated method builds on machine-learning -guided image analysis with SARS-CoV-2 as the model pathogen. The method enables simultaneous measurement of IgM, IgA, and IgG responses against different virus antigens in a high throughput manner. The assay relies on antigens expressed through transfection and allows for differentiation between vaccine-induced and infection-induced antibody responses. The transfection-based antigen expression enables performing the assay at a low biosafety level laboratory and allows fast adaptation of the assay to emerging pathogens. Our results provide proof-of-concept for the approach, demonstrating fast and accurate measurement of antibody responses in a clinical and research set-up.Competing Interest StatementPatent application has been filed for the method described in the manuscript.Funding StatementThis study was funded by LENDULET-BIOMAG Grant (2018-342), the European Regional Development Funds (GINOP-2.3.2-15-2016-00006, GINOP-2.3.2-15-2016-00026, GINOP-2.3.2-15-2016-00037), from the H2020-discovAIR (874656), the H2020 ATTRACT-SpheroidPicker, the Chan Zuckerberg Initiative Seed Networks for the HCA-DVP, the Finnish TEKES FiDiPro Fellow Grant 40294/13 (VP, OK, LP, PH), grants awarded by the Academy of Finland (iCOIN-336496: OK, VP, OV; 308613: JH; 321809: TS; 310552: LP; 337530: IJ, FIRI2020-337036: FIMM-HCA, AH, LP, VP, PH), the EU H2020 VEO project (OV), Minerva Foundation COVID-19 research project grant (VP), the Academy of Finland Flagship programme (CG, Finnish Center for Artificial Intelligence), and NKFIH grants (2020-1.1.6-JOVO-2021-00010, and TKP2020-NKA-17) to OrthoSera Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committees of Helsinki University Hospital (permit HUS/211/2020 and ethics committee approval HUS/853/2020 and HUS/1238/2020) and of the Hungarian Medical Research Council (clearance numbers IV/3457-2/2020/EKU and IV/3757-4/2020/EKU) gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. https://fimm-covid-19-hca.github.io/ http://86.50.253.10:8888/ https://dx.doi.org/10.5281/zenodo.6352550 ER -